2020
Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer.
Kelly K, Daly M, Mirhadi A, Lara F, Garcia L, Chen S, Eastham D, Wiegner E, Riess J, Schalper K, Monjazeb A. Atezolizumab plus stereotactic ablative therapy for medically inoperable patients with early-stage non-small cell lung cancer. Journal Of Clinical Oncology 2020, 38: 9011-9011. DOI: 10.1200/jco.2020.38.15_suppl.9011.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic ablative radiation therapyEarly-stage non-small cell lung cancerImmune checkpoint inhibitorsStage non-small cell lung cancerPD-L1 expressionCell lung cancerFlat dosingLung cancerInoperable early-stage non-small cell lung cancerRandomized phase III trialEarly-stage NSCLC patientsQuantitative immunofluorescenceAdditional efficacy outcomesCycles of atezolizumabDose level 2Grade 3 pneumonitisMedian age 77Mild toxicity profileSerial blood analysesPhase II doseGrade 3 rashPhase III trialsStage NSCLC patientsAblative radiation therapy
2017
Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images
Wang X, Janowczyk A, Zhou Y, Thawani R, Fu P, Schalper K, Velcheti V, Madabhushi A. Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images. Scientific Reports 2017, 7: 13543. PMID: 29051570, PMCID: PMC5648794, DOI: 10.1038/s41598-017-13773-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedArea Under CurveCarcinoma, Non-Small-Cell LungCell NucleusCohort StudiesDiscriminant AnalysisFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisProportional Hazards ModelsRetrospective StudiesROC CurveTissue Array AnalysisConceptsNon-small cell lung cancerEarly-stage non-small cell lung cancerStage non-small cell lung cancerEarly-stage NSCLC patientsStage NSCLC patientsCell lung cancerPrediction of recurrenceDisease recurrenceNSCLC patientsLung cancerTissue microarrayMultivariable Cox proportional hazards modelsCox proportional hazards modelTraditional prognostic variablesIndependent prognostic factorIdentification of patientsProportional hazards modelAdjuvant therapyNodal statusPrognostic factorsRetrospective cohortValidation cohortTraining cohortPrognostic variablesHigh risk